Top 10 Integrated Utility Companies To Watch In Right Now

Want to see what happens to an airplane manufacturing company after yet another one of its aircraft bursts into flames on the tarmac?

That's an intraday chart of Boeing (NYSE: BA  ) . The cliff you see around noon corresponds to news that yet another of its flagship 787 Dreamliners caught fire on an airport tarmac -- to be clear, the plane was empty at the time of the fire. For those of you that are counting, this is now the third such incident since the 787 began its commercial life.

According to The New York Times, "An internal fire broke out on Friday on a Boeing 787 that Ethiopian Airlines had parked between flights at London's Heathrow Airport." While it remains to be seen what caused the fire, this isn't good.

It was only seven weeks ago that the innovative aircraft was allowed back in the skies by global regulators following two similar occurrences earlier this year. In the first, a lithium-ion battery caught fire on a 787 parked at the Boston airport in the beginning of January. One week later, the same thing happened mid-flight, causing a 787 to make an emergency landing in Japan.

Top 10 Integrated Utility Companies To Watch In Right Now: Asia Bio-Chem Group Corp(ABC.TO)

Asia Bio-Chem Group Corp., through its subsidiaries, engages in the manufacture, packaging, and sale of cornstarch, germ, fiber, and gluten in People?s Republic of China. The company?s cornstarch is used in manufacturing food products, including MSG, fructose, maltose, glucose, dextrin, citric acid, and lysine. Its cornstarch is also used to produce sugar alcohols, such as sorbitol and mannitol, as well as to produce various modified starch products for the pharmaceutical and fine chemical industries. The company?s corn germ is used for producing margarine or corn oil for cooking; and gluten and fiber products are used by livestock farmers as animal feed. Asia Bio-Chem Group Corp. is headquartered in Shenyang, the People?s Republic of China.

Top 10 Integrated Utility Companies To Watch In Right Now: Fomento de Construcciones y Contratas SA (FCC)

Fomento de Construcciones y Contratas SA (FCC) is a Spain-based company, which is primarily engaged, together with its subsidiaries in the construction and environmental services sector. The Company�� activities include the collection, treatment and elimination of solid urban waste, street cleaning, sewer system maintenance, green areas and buildings maintenance, urban transport, treatment and elimination of industrial waste, full-service water supply management and cement manufacture. The Company is also active in the real estate development, as well as in the renewable energy industry. In addition, the Company is a parent of Grupo FCC, a group which comprises a number of controlled entities.

Top 5 Telecom Stocks To Invest In Right Now: Shore Gold Inc Com Npv (SGF.TO)

Shore Gold Inc., an explorations stage company, engages in the acquisition, exploration, and development of mineral properties. It principally explores for diamond. The company primarily focuses on the exploration of the Star � Orion South diamond project located in the Fort � la Corne Provincial Forest, Saskatchewan, Canada. It also holds a 33% interest in the Buffalo Hills property located in northern Alberta, Canada. The company was formerly known as Shore Gold Fund Inc. and changed its name to Shore Gold Inc. in August 1994. Shore Gold Inc. was incorporated in 1985 and is headquartered in Saskatoon, Canada.

Top 10 Integrated Utility Companies To Watch In Right Now: Bodaclick SA (BDK.MC)

Top 10 Integrated Utility Companies To Watch In Right Now: Solarvest Bioenergy Inc (SVS.V)

Solarvest BioEnergy Inc., through its subsidiaries, engages in the research and development of alternate energy. The company focuses on the development of sustainable and renewable energy sources. Its technology provides a controlled method for turning on and off genes in algae resulting in the continuous production of hydrogen gas. Solarvest BioEnergy Inc. is based in Vancouver, Canada.

Top 10 Integrated Utility Companies To Watch In Right Now: Motricity Inc.(MOTR)

Motricity, Inc. enables mobile operators, brands, and advertising agencies to maximize the reach and economic potential of the mobile ecosystem through the delivery of relevance-driven merchandising, marketing, and advertising solutions. It leverages predictive analytics capabilities to deliver the right content, to the right person at the right time. Motricity, Inc. provides their entire suite of mobile data service solutions through a managed service platform. The company was formerly known as Power By Hand, Inc. and changed its name to Motricity, Inc. in October 2004. Motricity, Inc. was incorporated in 2004 and is headquartered in Bellevue, Washington.

Top 10 Integrated Utility Companies To Watch In Right Now: Sahara Energy Ltd (SAH.V)

Sahara Energy Ltd., a junior resource exploration company, engages in the acquisition, exploration, and development of petroleum and natural gas reserves in western Canada. It focuses on the exploration and evaluation of various oil and gas properties in Saskatchewan and Alberta. The company is headquartered in Calgary, Canada. On March 23, 2010, Sahara Energy, Ltd. filed for bankruptcy under the Bankruptcy and Insolvency Act (Canada).

Top 10 Integrated Utility Companies To Watch In Right Now: Quest Diagnostics Inc (DGX)

Quest Diagnostics Incorporated (Quest Diagnostics), incorporated in 1990, is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides interpretive consultation through the medical and scientific staff. The Company is a provider of clinical testing, including gene-based and esoteric testing and anatomic pathology services, and the provider of risk assessment services for the life insurance industry. The Company also is a provider of testing for clinical trials and testing for drugs of abuse. Its diagnostics products business manufactures and markets diagnostic test kits and specialized point-of-care testing. On April 4, 2011, the Company acquired Athena Diagnostics (Athena). On May 17, 2011, the Company acquired Celera Corporation (Celera). In January 2012, the Company acquired S.E.D. Medical Laboratories. In December 2012, the Company sold all of the assets of OralDNA Labs salivary-diagnostics business to Access Genetics. Quest Diagnostics Incorporated (Quest Diagnostics) is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides interpretive consultation through the medical and scientific staff. The Company is a provider of clinical testing and the provider of risk assessment services for the life insurance industry. The Company also is a provider of testing for clinical trials and testing for drugs of abuse. In January 2012, it acquired S.E.D. Medical Laboratories. In December 2012, it sold all of the ! assets of OralDNA Labs salivary-diagnostics business to Access Genetics. In January 2013, the Company acquired the Worcester -based clinical outreach laboratory business of UMass Memorial Medical Center.

Clinical Testing

The Company is a commercial clinical testing company. Physicians use clinical tests to assist in the detection, diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions. Clinical testing is generally categorized as clinical laboratory testing and anatomic pathology services. The Company offers customers the access to the test menu of clinical laboratory and anatomic pathology tests in the United States. Clinical laboratory testing generally is performed on whole blood, serum, plasma and other body fluids, such as urine, and specimens such as microbiology samples.

The Company is a provider of routine clinical testing, including testing for drugs of abuse. The Company performs routine testing through its network of laboratories and rapid response laboratories. The Company also performs routine testing at hospital laboratories that the Company manages. The Company operates laboratories round the clock. The majority of test results are delivered electronically. Routine tests measure various bodily health parameters, such as the functions of the kidney, heart, liver, thyroid and other organs. Commonly ordered tests include blood chemistries, including cholesterol levels; complete blood cell counts; urinalysis; pregnancy and other prenatal tests, and routine microbiology testing.

The Company is a provider of anatomic pathology services in the United States, through its AmeriPath, Dermpath Diagnostics and Quest Diagnostics brands. Anatomic pathology involves the diagnosis of cancer and other diseases and medical conditions through examination of tissue and cell samples taken from patients. The Company provides inpatient anatomic pathology and medical director services at hospitals throughout the country, and through ! its labor! atories. The Company provides a range of services to all anatomic pathology subspecialties. The Company provides integrated, reports that include both anatomic pathology and clinical pathology tests, enabling its pathologists to offer patients and physicians a complete analysis. The Company introduced the Leumeta family of tests for leukemia and lymphoma.

The Company is a provider in the United States of gene-based and esoteric testing. Esoteric tests include procedures in the areas of molecular diagnostics, protein chemistry, cellular immunology and advanced microbiology. Commonly ordered esoteric tests include viral and bacterial detection tests, drug therapy monitoring tests, genetic tests, autoimmune panels and complex cancer evaluations. During the year ended December 31, 2011, it acquired Athena Diagnostics, a provider of neurology testing. Its esoteric laboratories provide reference testing services to physicians, academic medical centers, hospitals and other commercial laboratories. The Company also offers gene-based tests for the predisposition, diagnosis, treatment and monitoring of cancers. The Company develops tests at its laboratories, such as Quest Diagnostics Nichols Institute. It also develops techniques and services in anatomic pathology.

In 2011, the Company introduced its melanoma treatment selection mutation panel, which is designed to assist in the personalized selection of patient therapies. The Company introduced its thyroid cancer mutation panel, which assists in the diagnosis of thyroid cancer and aids physicians and surgeons as they plan surgery and other therapies to treat and attempt to cure thyroid cancer. During 2011, it enhanced its SureSwab Vaginosis/Vaginitis Plus test. The Company introduced Accutype IL28b, a test designed to aid in the prediction of patient response to peginterferon alpha-based therapy for treating hepatitis C virus infection. In 2011, it introduced testing for very long chain fatty acids, to assist in diagnosis and monitori! ng of inh! erited disorders of fatty acid metabolism. It also introduced high resolution chromosomal analysis testing with oligonucleotide microarrays to enhance its testing services in the pre-natal and post-natal genetics areas. During 2011, the Company released a test for therapeutic drug monitoring of dabigatran, an oral anti-coagulant. The Company also released genetic testing for SLC01B1, which helps identify patients at risk for myopathy from Simvastatin therapy for cholesterol reduction. Through Athena Diagnostics, it launched several molecular genetic tests for stroke, neuromuscular diseases and mitochondrial disorders.

Healthcare Information Technology

The Company provides interoperable technologies that help healthcare organizations and physicians enter, share and access clinical information without costly information technology (IT) implementation or workflow disruption, including through its Care360 suite of products and its ChartMaxx electronic document management system for hospitals. These solutions offer access to a national healthcare provider network, including approximately 200,000 networked physicians and clinicians using Quest Diagnostics��Care360 connectivity products. The Care360 products, including its Care360 Labs and Meds, enable physicians electronically to order diagnostic tests and review test results from Quest Diagnostics and electronically to prescribe medication. As of December 31, 2011, prescriptions were written through Care360 ePrescribing at an annualized rate of 32 million medications. Using its Care360 connectivity products, physicians can securely provide diagnostic and other data to a patient�� account. It offers Gazelle, a secure mobile health platform that allows users to receive their Quest Diagnostics laboratory results, manage their personal health information, find a Quest Diagnostics location and schedule appointments directly from their smartphone.

Clinical Trials Testing

The Company is a provider of central l! aboratory! testing performed in connection with clinical research trials on new drugs, vaccines and certain medical devices. It has clinical trials testing centers in the United States and the United Kingdom, and it provides clinical trials testing in Argentina, Australia, Brazil, the People�� Republic of China and Singapore through affiliated laboratories. The Company has biomarker capabilities. In 2011, it acquired Celera, enhancing its ability to provide biomarker discovery and develop IVD test kits.

Life Insurer Services

The Company is a provider of risk assessment services to the life insurance industry in North America. It also provides risk assessment services for insurance companies doing business in many countries outside the United States. Its risk assessment services comprise underwriting support services to the life insurance industry, including laboratory testing, electronic data collection, specimen collection and paramedical examinations, medical record retrieval, case management, motor vehicle reports, telephone inspections, prescription histories and credit checks. The laboratory tests that it performs and data it gathers are designed to assist insurance companies to objectively evaluate the mortality risks of policy applicants. The majority of the testing is performed on specimens of life insurance applicants, but also includes specimens of applicants for other types of insurance. Most of its specimen collections and paramedical examinations are performed by its network of approximately 5,000 contracted paramedical examiners at the applicant�� home or workplace. The Company also offers paramedical examinations through approximately 500 of its patient service centers, and operate approximately 80 locations other than patient service centers in the United States and Canada where the Company provides paramedical examinations, bringing to approximately 580 the total number of sites where it can provide these examinations. The Company also contracts with third parties at over! an addit! ional 200 locations globally to coordinate providing these exams.

Employer Services

The Company is a provider of testing to employers for the detection of employee use of drugs of abuse. Its Quest Diagnostics Drug Testing Index, which is an annual report of its aggregate drug testing results, is used by employers, the federal government and the media to help identify and quantify drug abuse among the nation�� workforce. It provides a range of solutions for drugs of abuse, including urine, hair, blood and oral fluid tests. In 2011, it introduced Oral-Eze, its own oral fluid collection system that simplifies the collection of oral samples for routine drug testing. The Oral-Eze Oral Fluid Collector provides all the advantages of previous collection systems, with the added benefit of its indicator window technology. The Company provides wellness testing and analytic services to employers.

Diagnostic Products

Diagnostic Products include point-of-care, or near-patient and testing. The Company develops and manufactures products that enable healthcare professionals to make healthcare diagnoses, including products for point-of-care, or near-patient, testing for the professional market. The Company has several companies, including Focus Diagnostics, HemoCue and Celera. Focus Diagnostics is a provider of infectious disease testing. Focus Diagnostics develops, manufactures and markets diagnostic products, such as HerpeSelect ELISA tests that detect patient antibodies to specific types of herpes simplex virus, which can be performed on a variety of instrument platforms. Focus Diagnostics sells its diagnostic products to academic medical centers, hospitals and commercial laboratories globally. Focus Diagnostics has an agreement with 3M Corporation for global human diagnostic rights to a compact integrated bench-top instrument for use with real time polymerase chain reaction (PCR) assays. These tests are sold under the Simplexa brand name. In 2011, Focus Diagnostic! s receive! d the CE mark to offer Simplexa tests in Europe, including tests for Cytomegalovirus, Epstein Barr virus, BK virus and clostridium difficile. Focus Diagnostics offers molecular transplant-testing menus in Europe.

HemoCue manufactures and distributes point-of-care testing products globally. HemoCue is a global provider in point-of-care testing for hemoglobin, with a growing market share for glucose, microalbumin and white blood cell testing. HemoCue offers its White Blood Cell Differential System in Europe. Celera offers complexity molecular diagnostic products in segments, such as HIV-1 drug resistance testing, reproductive genetics, transplantation and cardiovascular genetics. It also manufactures and offers the InSure fecal immunochemical test (FIT) for screening for colorectal cancer.

The Company competes with Laboratory Corporation of America Holdings, Inc.

Advisors' Opinion:

• [By Monica Gerson]

  Quest Diagnostics (NYSE: DGX) is projected to report its Q3 earnings at $1.17 per share on revenue of $1.82 billion.

  Valmont Industries (NYSE: VMI) is expected to post its Q3 earnings at $2.43 per share on revenue of $800.97 million.

• [By Ben Fox Rubin]

  Medical-testing services provider Quest Diagnostics Inc.(DGX) raised the low end of its 2013 profit estimate, a rosier view that comes two days after rival Laboratory Corp. of America Holdings issued a disappointing 2014 outlook.

Top 10 Integrated Utility Companies To Watch In Right Now: Hartco Income Fd(HCI.TO)

Hartco Inc., through its subsidiaries, provides information technology products, services, and solutions to private and public organizations in Canada. It operates in two segments, Franchising and Distribution, and Commercial. The Franchising and Distribution segment offers logistics, marketing, and other services to its franchise network partners in Canada. It is also involved in distribution activities; and the franchising of businesses that sell a range of IT infrastructure solutions. This segment?s franchises operate under the banners of Metafore and MicroAge. The Commercial segment, through its subsidiary, Metafore Technologies Inc., designs, supplies, installs, and supports IT infrastructure solutions. The company was founded in 2000 and is headquartered in Montreal, Canada.